Immunotherapy and Providence Cancer Center featured in Portland Business Journal

July 11, 2014
In the cover story of the July 11, 2014 issue, the Portland Business Journal explores the current state of cancer treatments and the role Portland researchers are playing in new research.
 
Dr. Bernard Fox, chief of the Laboratory of Molecular and Tumor Immunology in the Earle A. Chiles Research Institute at Providence Cancer Center, talks about how partnerships with pharmaceutical companies have helped advance the development of immune-boosting drugs such as Anti-OX40 – a treatment for melanoma that, in four years, has increased the two-year patient survival rate from 22 percent to 78 percent.
 
Read the full story from the Portland Business Journal.